IKT earnings: a positive outcome, +8.5%

On November 14, 2022, Inhibikase Therapeutics, Inc. reached its earnings. The result was a positive outcome, and the stock moved +8.5% in the window around the event. It had already run -39.5% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.